Vir Biotechnology, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VIR Nasdaq 2830 www.vir.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vir Biotechnology, Inc.

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - Aug 12th, 2026 3:28 pm
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary - Aug 6th, 2026 6:30 am
Vir Biotechnology Q2 Earnings Call Highlights - Aug 6th, 2026 1:03 am
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ... - Aug 5th, 2026 11:08 pm
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates - Aug 5th, 2026 6:35 pm
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Aug 5th, 2026 2:05 pm
Vir Biotechnology (VIR) Could Be 60% Undervalued On CFO Transition - Jul 31st, 2026 6:14 pm
Vir Biotechnology Announces Chief Financial Officer Transition - Jul 24th, 2026 6:30 am
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results - Jul 22nd, 2026 2:05 pm
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B - Jul 2nd, 2026 6:00 pm
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors - Jun 26th, 2026 5:00 am